Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables, and is considered to be a potent antioxidant with several expected health benefits such as anti-inflammatory effects and bone-conserving properties. Participants will supplement with either Quercetin, or placebo, for 90-days with pre- and post-testing visits.
Quercetin is a plant-based flavonoid that is naturally found in many fruits and vegetables such as onions, apples, berries, green tea, and red wine and is currently an FDA approved supplement. Quercetin is considered to be a potent antioxidant with several expected health benefits. Both in vivo and in vitro studies have demonstrated that quercetin acts as a potent natural osteogenic agent with benefits that include anti-inflammatory effects and bone-conserving properties. Quercetin is suggested to protect against bone loss by inhibiting bone resorption and stimulating bone formation which is indicated by an increase in bone mineral density and bone formation markers such as osteocalcin.
The purpose of this study is to investigate the effects of quercetin supplementation on bone, specifically on bone turnover markers, in postmenopausal women. The interplay between cytokines (i.e., IL-6, CRP, and TNF-alpha) and bone turnover markers was also considered.
In a double-blind, placebo-controlled fashion, we aimed to recruit 50, healthy, postmenopausal women between the ages of 45-75 years to participate in a 90-day supplement trial. Participants will be randomly assigned to one of two supplement groups: 1) quercetin 500 mg, once per day, or 2) placebo (methyl cellulose E4M) 500 mg, once per day for 90-days.
Participants will be asked to visit the laboratory (KSU Human Performance Laboratory) on 2 separate occasions for pre- and post-testing visits consisting of body composition measurements and blood draws by a CITI approved/IRB approved research team member trained in phlebotomy under the supervision of Dr. VanDusseldorp.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Postmenopausal women: Experimental group | Experimental | Quercetin 500 mg. One capsule once a day. |
|
| Postmenopausal women: Placebo group | Placebo Comparator | Placebo (methylcellulose E4M) 500 mg, once capsule once a day. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quercetin (500 mg) | Dietary Supplement | Once-daily 500 mg Quercetin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Osteocalcin ng/mL | Bone formation marker | 90-days |
| PINP ug/L | Procollagen type-I N-terminal propeptide. Bone formation marker. | 90-days |
| CTX ng/L | Type-I collagen cross-linked C-terminal telopeptide. Bone resorption marker. | 90-days |
| IL-6 pg/mL | Interleukin-6 inflammatory marker. | 90-days |
| TNF-alpha pg/mL | Tumor necrosis factor-alpha inflammatory marker | 90-days |
| CRP mg/L | C-reactive protein inflammatory marker. | 90-days |
| FBG mg/dl | Fasting blood glucose | 90-days |
| BMD g/cm^2 | Total, lumbar, right and left femur, and left forearm bone mineral density | 90-days |
| Measure | Description | Time Frame |
|---|---|---|
| Body composition | body fat percentage | 90-days |
| Timed up and go (seconds) | Physical function test | 90-days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kennesaw State University | Kennesaw | Georgia | 30144 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40053115 | Derived | Bailly AR, Hester GM, Alesi MG, Buresh RJ, Feito Y, Mermier CM, Ducharme JB, VanDusseldorp TA. Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women. J Bone Miner Metab. 2025 May;43(3):304-314. doi: 10.1007/s00774-025-01592-0. Epub 2025 Mar 7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015663 | Osteoporosis, Postmenopausal |
| ID | Term |
|---|---|
| D010024 | Osteoporosis |
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011794 | Quercetin |
| ID | Term |
|---|---|
| D044948 | Flavonols |
| D005419 | Flavonoids |
| D002867 | Chromones |
| D001578 | Benzopyrans |
| D011714 |
Not provided
Not provided
Double blind placebo controlled
Not provided
Not provided
Not provided
| Placebo (500 mg) | Other | Once-daily 500 mg methylcellulose 9E4M) |
|
| Dominant handgrip strength (kg) | Physical function test | 90-days |
| D008659 |
| Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |